Inozyme Pharma, Inc. , a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases.
Inozyme Pharma stock last closed at $4.61, up 4.54% from the previous day, and has decreased 20.65% in one year. It has overperformed other stocks in the Biotechnology industry by 0 percentage points. Inozyme Pharma stock is currently +71.44% from its 52-week low of $2.69, and -40.86% from its 52-week high of $7.80.
As of May 1, 2024, there are 61.77M shares of INZY outstanding. The market capitalization of INZY is $284.77M. In the past 24 hours, 510,700 INZY shares were traded.
You will need a brokerage account in order to access the NASDAQ market and buy INZY shares.
Based on our experience, eToro is the best online stock brokerage. Here's why:
Get $10 towards your share purchase by opening an account with eToro today.
Open eToro AccountNow that you've selected the right brokerage, it's time to fill out some personal information so you are able to buy INZY stock today.
Now that you've created your account on investing apps, your next step is to transfer the money for your investment:
Watch the walkthrough below for more details depositing money into your brokerage account.
After you have selected the best place to buy Inozyme Pharma stock, it's important to research their stock before you invest, so you actually wrap your head around the risk as well as the upside.
WallStreetZen was designed to help everyday investors do more accurate fundamental analysis.
You can view all of the due diligence checks on INZY's stock page.
Investors use many financial metrics, analyses, models, and charts to gauge INZY's intrinsic value.
Using relative valuations measures:
You can do more valuation analysis on INZY's stock here.
Out of 4 Equities analysts who monitor INZY, the consensus analyst rating on INZY is a Strong Buy
Please note that analyst forecasts are not stock recommendations, nor are they investment advice.
You can dig deeper into what analysts are projecting on the Inozyme Pharma stock forecast page.
Over the past 12 months, insiders at INZY have bought more shares than they have sold.
Douglas A. Treco, CEO of INZY, was the latest INZY insider to sell. They sold $52,209.62 worth of INZY shares on Apr 2, 2024.
Research more about who owns INZY shares here.
No, Inozyme Pharma doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
You have two main options:
Hit the Open Trade button and eToro will place the order.
If you need more assistance investing in stocks on eToro, watch the how to video below:
Now that you own some INZY stock, you'll want to keep up with your shares.
Create a watchlist to track the most important metrics related to your INZY stock.
To reiterate, here are the 6 steps you need to take to buy Inozyme Pharma stock right now:
If you require a brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to monitor your new investment in Inozyme Pharma, create a watchlist on WallStreetZen today.